Takeda: Multiple Myeloma trials

The registry lists 54 Multiple Myeloma studies with Takeda as lead sponsor. 2 are open to participants now and 33 have results posted.

Phase 1 18Phase 2 13Phase 3 11Phase 4 4No phase 14(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple MyelomaRecruitingNCT06980480Phase 3
• Real-world Usage of HyQvia in Multiple Myeloma Adults With Secondary ImmunodeficiencyRecruitingNCT05879757
• A Survey on NINLARO Risk Management Plan (RMP) Material Utilization Among Pharmacists in JapanCompletedNCT05882279Results posted
• A Study Of TAK-981 Given With Monoclonal Antibodies (mAbs) In Adults With Relapsed or Refractory Multiple Myeloma (RRMM)TerminatedNCT04776018Phase 1/2Results posted
• A Study of MLN9708 in Japanese Participants With Relapsed and/or Refractory Multiple Myeloma (RRMM)TerminatedNCT04272775Phase 1Results posted
• Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Participants With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation (SCT)CompletedNCT03748953Phase 3Results posted
• Multiple Myeloma (MM) Profile in Brazil: A Retrospective Observational AnalysisCompletedNCT03506386Results posted
• A Study of Ixazomib+Daratumumab+Dexamethasone (IDd) in Relapsed and/or Refractory Multiple Myeloma (RRMM)CompletedNCT03439293Phase 2Results posted
• A Study to Investigate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of TAK-079 Administered Subcutaneously as a Single Agent in Participants With Relapsed/Refractory (r/r) Multiple Myeloma (MM)CompletedNCT03439280Phase 1/2Results posted
• A Study in Relapsed and/or Refractory Multiple Myeloma Patients Treated With Ixazomib Plus Lenalidomide and DexamethasoneCompletedNCT03433001Results posted
• A Study to Evaluate the Efficacy and Safety of Ixazomib in Combination With Lenalidomide and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma Initially Treated With an Injection of Proteasome Inhibitor-Based TherapyCompletedNCT03416374Phase 4Results posted
• Clinical and Sociodemographic Characterization of Multiple Myeloma Participants With Symptomatic Relapse and/or Refractory Disease in Spain (CharisMMa Study)CompletedNCT03188536Results posted
• A Study of Ixazomib, Given With Dexamethasone in Adults With Multiple MyelomaCompletedNCT03170882Phase 2Results posted
• NINLARO Capsules Drug Use-Results Survey (All-Case Surveillance) "Relapsed/Refractory Multiple Myeloma"CompletedNCT03169361Results posted
• Ixazomib Rollover StudyCompletedNCT02924272Phase 2Results posted
• A Study of Ixazomib Plus Lenalidomide and Dexamethasone in Adult Japanese Participants With Relapsed and/or Refractory Multiple MyelomaCompletedNCT02917941Phase 2Results posted
• An Observational Study of Presentation, Treatment Patterns, and Outcomes in Multiple Myeloma ParticipantsTerminatedNCT02761187Results posted
• A Study of Oral Ixazomib Maintenance Therapy in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Not Treated With Stem Cell Transplantation (SCT)CompletedNCT02312258Phase 3Results posted
• A Study of Oral Ixazomib Citrate (MLN9708) Maintenance Therapy in Participants With Multiple Myeloma Following Autologous Stem Cell TransplantCompletedNCT02181413Phase 3Results posted
• Phase 2 Study to Evaluate the Oral Combination of Ixazomib (MLN9708) With Cyclophosphamide and Dexamethasone in Patients With Newly Diagnosed or Relapsed and/or Refractory Multiple MyelomaCompletedNCT02046070Phase 2Results posted
• IXAZOMIB Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Newly Diagnosed Multiple MyelomaCompletedNCT01850524Phase 3Results posted
• Pharmacokinetics Study of Oral Ixazomib (MLN9708) in Relapsed/Refractory Multiple Myeloma and Advanced Solid Tumors Participants With Normal Renal Function or Severe Renal ImpairmentCompletedNCT01830816Phase 1Results posted
• Phase 1 Pharmacokinetic Study of Oral Ixazomib Plus Lenalidomide and Dexamethasone in Adult Asian Participants With Relapsed and/or Refractory Multiple MyelomaCompletedNCT01645930Phase 1Results posted
• A Phase 3 Study Comparing Oral Ixazomib Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple MyelomaCompletedNCT01564537Phase 3Results posted
• Study of Oral IXAZOMIB in Combination With Lenalidomide and Dexamethasone in Participants With Newly Diagnosed Multiple MyelomaCompletedNCT01383928Phase 1/2Results posted
• Study of Oral Ixazomib in Combination With Melphalan and Prednisone in Participants With Newly Diagnosed Multiple MyelomaCompletedNCT01335685Phase 1/2Results posted
• A Study of Ixazomib Administered in Combination With Lenalidomide and Low-Dose Dexamethasone in Patients With Newly Diagnosed Multiple MyelomaCompletedNCT01217957Phase 1/2Results posted
• Study Evaluating the Safety and Tolerability of Weekly Dosing of Oral IXAZOMIB in Adult Patients With Relapsed and Refractory Multiple MyelomaCompletedNCT00963820Phase 1Results posted
• Study of Oral Ixazomib in Adult Participants With Relapsed and/or Refractory (RR) Multiple MyelomaCompletedNCT00932698Phase 1Results posted
• A Study of Subcutaneous and Intravenous VELCADE in Patients With Previously Treated Multiple MyelomaCompletedNCT00722566Phase 3Results posted
• Study of MLN8237 in Participants With Advanced Hematological MalignanciesCompletedNCT00697346Phase 1Results posted
• An Open-Label Study to Assess the Effect of CYP3A4 Induction on the Pharmacokinetics of VELCADE (Bortezomib)CompletedNCT00608907Phase 1Results posted
• A Study to Evaluate Two Different Regimens of VELCADE in Combination With Dexamethasone, Thalidomide and Cyclophosphamide (VDT vs VDTC) in Newly Diagnosed Multiple MyelomaCompletedNCT00531453Phase 2Results posted
• Phase 1/2 Study of VELCADE® in Combination With Other Drugs to Treat Previously Untreated Multiple Myeloma PatientsCompletedNCT00507442Phase 1/2Results posted
• Velcade,Thalidomide, and Dexamethasone Versus Velcade and Dexamethasone Versus Velcade, Melphalan, and PrednisoneCompletedNCT00507416Phase 3Results posted
• A Multicenter In-class Transition Study of Ixazomib Combined With Pomalidomide and Dexamethasone or With Lenalidomide and Dexamethasone in Adults With Relapsed/Refractory Multiple MyelomaWithdrawnNCT05183139Phase 4
• A Study of NINLARO® in Chinese Adults With Multiple MyelomaActive, not recruitingNCT05013190
• A Study of Real Life Treatment for Multiple Myeloma (MM)Active, not recruitingNCT04985643
• A Study of Real-World Use of Ixazomib Citrate in People With Multiple Myeloma (MM)CompletedNCT04840680
• A Study to Investigate the Relationship Between Duration of Treatment and Response in Patients With Multiple Myeloma (MM) or Systemic AL Amyloidosis Treated in Real-life PracticeCompletedNCT04659798
• A Study of Ninlaro in Real World Clinical Practice in ChinaCompletedNCT04328662
• A Study of People With Multiple Myeloma (MM) in Portugal (CharisMMa-Portugal)CompletedNCT04135963
• A Study to Evaluate Subcutaneous TAK-079 Added to Standard of Care Regimens in Participants With Newly Diagnosed Multiple Myeloma (NDMM)CompletedNCT03984097Phase 1
• A Study of Ixazomib, Thalidomide and Dexamethasone in Newly Diagnosed and Treatment-naive Multiple Myeloma (MM) Participants Non-eligible for Autologous Stem-cell TransplantationWithdrawnNCT03608501Phase 2
• A Study of Ixazomib (NINLARO®) in Combination With Lenalidomide and Dexamethasone (IRD) for the Treatment of Participants With Multiple Myeloma (MM)TerminatedNCT03173092Phase 4
• Dose Escalation Study of MLN0128 in Relapsed or Refractory Multiple Myeloma or Waldenstrom MacroglobulinemiaCompletedNCT01118689Phase 1
• A Phase 1 Dose Escalation Study of TAK-901 in Subjects With Advanced Hematologic MalignanciesCompletedNCT00807677Phase 1
• Study of MLN4924, a Novel Inhibitor of Nedd8 Activating Enzyme, in Adult Patients With Lymphoma or Multiple MyelomaCompletedNCT00722488Phase 1
• Evaluation of VELCADE Given as Retreatment to Multiple Myeloma Patients for Efficacy, Safety and TolerabilityCompletedNCT00257114Phase 4
• VELCADE/Melphalan/Prednisone Versus Melphalan/Prednisone in Patients With Previously Untreated Multiple MyelomaCompletedNCT00111319Phase 3
• Repeat-Dose Pharmacokinetics and Pharmacodynamics of Bortezomib in Patients With Relapsed Multiple MyelomaCompletedNCT00080405Phase 1
• A Study to Assess Two Different Strategies of Combining Dexamethasone and VELCADENo longer availableNCT00063791
• A Study of PS-341 Given to Patients With Multiple Myeloma Who Experienced Progressive Disease After Receiving Dexamethasone in M34101-039CompletedNCT00063726Phase 3
• PS-341 (VELCADE™) Versus High-Dose Dexamethasone in Patients With Relapsed or Refractory Multiple MyelomaCompletedNCT00048230Phase 3